<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 17.1: Intersecting Pathologies: PCOS and Autoimmune Thyroiditis</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - DEEP BLUE/PURPLE theme for Complex Scenarios */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Objectives Box */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #3b82f6, #1e3a8a);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Data Table */
        .data-table-container {
            margin: 30px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f3f4f6;
            padding: 15px;
            font-weight: 600;
            color: #1e3a8a;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #e5e7eb;
            vertical-align: top;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Stats Box */
        .stat-highlight {
            background: #1e3a8a;
            color: white;
            padding: 30px;
            border-radius: 14px;
            margin: 35px 0;
            display: flex;
            flex-direction: column;
            align-items: center;
            text-align: center;
        }

        .stat-value {
            font-size: 36px;
            font-weight: 700;
            margin-bottom: 10px;
            color: #D4A84B;
        }

        /* Check Your Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f0f8f0;
            border-radius: 8px;
            border-left: 4px solid #2e7d32;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f3f4f6;
            padding: 25px;
            border-radius: 12px;
            margin: 40px 0;
        }

        .references-box {
            background: #ffffff;
            border-top: 1px solid #eee;
            padding: 30px 0;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            color: #333;
            margin-bottom: 15px;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 120px;
            opacity: 0.8;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 17: Advanced Clinical Mastery</p>
            <h1 class="lesson-title">Intersecting Pathologies: PCOS and Autoimmune Thyroiditis</h1>
            <div class="lesson-meta">
                <span class="meta-item">‚è±Ô∏è 35 min read</span>
                <span class="meta-item">üìö Lesson 17.1</span>
                <span class="meta-item">üéì Level: Advanced Practitioner</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#intro"><span class="section-num">1</span>The "Double-O" Syndrome</a></li>
                <li><a href="#bloom"><span class="section-num">2</span>B.L.O.O.M. Method‚Ñ¢ Application</a></li>
                <li><a href="#diff"><span class="section-num">3</span>Differential Diagnosis Mastery</a></li>
                <li><a href="#supps"><span class="section-num">4</span>Advanced Supplementation Synergy</a></li>
                <li><a href="#cases"><span class="section-num">5</span>Case Management Protocols</a></li>
                <li><a href="#protocol"><span class="section-num">6</span>The 6-Month Roadmap</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Analyze the bidirectional mechanisms linking PCOS and Hashimoto‚Äôs Thyroiditis.</li>
                <li>Apply the B.L.O.O.M. Method‚Ñ¢ to prioritize inflammatory versus metabolic interventions.</li>
                <li>Execute a differential diagnosis between thyroid-driven and androgen-driven cycle irregularities.</li>
                <li>Design a targeted supplementation protocol using Myo-inositol, Selenium, and Vitamin D3/K2.</li>
                <li>Construct a 6-month clinical roadmap for clients with comorbid high TPO antibodies and elevated DHEA-S.</li>
            </ul>
        </div>

        <h2 id="intro">1. The "Double-O" Syndrome: PCOS and Hashimoto's</h2>
        <p>In clinical practice, Polycystic Ovary Syndrome (PCOS) and Hashimoto‚Äôs Thyroiditis (Autoimmune Thyroiditis) frequently present together‚Äîa phenomenon often referred to as the <span class="highlight">"Double-O" Syndrome</span>. This is not merely a coincidence; it is a manifestation of shared pathophysiological pathways involving immune dysregulation, insulin resistance, and endocrine crosstalk.</p>

        <div class="stat-highlight">
            <div class="stat-value">3-Fold Increase</div>
            <p>A 2022 meta-analysis involving over 15,000 participants found that women with PCOS are 3.2 times more likely to develop Hashimoto‚Äôs Thyroiditis compared to the general population (n=15,456; CI 95%).</p>
        </div>

        <p>The intersection occurs at three primary junctions:</p>
        <ul>
            <li><strong>Insulin Resistance:</strong> Hyperinsulinemia can stimulate the thyroid gland directly, leading to increased nodularity, while also driving ovarian androgen production.</li>
            <li><strong>Immune Dysregulation:</strong> Elevated Th17 cell activity and a decrease in T-regulatory cells are common to both pathologies, creating a pro-inflammatory environment that exacerbates both conditions.</li>
            <li><strong>Estrogen Dominance:</strong> Both conditions often feature a relative lack of progesterone, which is necessary to dampen the immune response and support thyroid peroxidase (TPO) function.</li>
        </ul>

        <h2 id="bloom">2. Applying the B.L.O.O.M. Method‚Ñ¢ to Comorbid Cases</h2>
        <p>When working with complex clients, the <span class="highlight">B.L.O.O.M. Method‚Ñ¢</span> provides a framework for prioritization. In a comorbid case, the "B" (Baseline Assessment) is critical for determining which pathology is currently the "lead" driver of symptoms.</p>

        <div class="principle-card" style="border-left-color: #1e3a8a;">
            <div class="principle-title">The B.L.O.O.M. Prioritization Rule</div>
            <p class="principle-text">When PCOS and Hashimoto's intersect, the <strong>Thyroid (Inflammation)</strong> usually takes precedence over <strong>PCOS (Insulin)</strong> in the first 60 days of intervention. Attempting to drive aggressive insulin-sensitizing protocols (like heavy fasting or intense HIIT) while TPO antibodies are high often triggers an HPA-axis flare, worsening both conditions.</p>
        </div>

        <p>During the <strong>Baseline Assessment (B)</strong>, we look for "The Tipping Point":
        <ul>
            <li>If TPO antibodies are &gt;500 IU/mL, focus on <strong>Gut Permeability and Inflammation</strong>.</li>
            <li>If Fasting Insulin is &gt;15 ¬µIU/mL but TPO is &lt;100 IU/mL, focus on <strong>Metabolic Flexibility</strong>.</li>
        </ul></p>

        <h2 id="diff">3. Differential Diagnosis: Thyroid vs. Androgen Drivers</h2>
        <p>One of the greatest challenges for a Hormone Health Coach is distinguishing between symptoms. Is the hair loss caused by high androgens (PCOS) or low T3 (Hashimoto's)? Is the irregular cycle due to anovulation from insulin or thyroid-driven signaling failure?</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Symptom</th>
                        <th>PCOS-Driven (Androgenic)</th>
                        <th>Hashimoto's-Driven (Thyroidal)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Hair Loss Pattern</strong></td>
                        <td>Vertex/Temple thinning (Male pattern)</td>
                        <td>Diffuse thinning + Outer 1/3 of eyebrow</td>
                    </tr>
                    <tr>
                        <td><strong>Weight Gain</strong></td>
                        <td>Central/Visceral (Apple shape)</td>
                        <td>Generalized + Myxedema (fluid retention)</td>
                    </tr>
                    <tr>
                        <td><strong>Cycle Pattern</strong></td>
                        <td>Long cycles (&gt;35 days) or Amenorrhea</td>
                        <td>Heavy bleeding (Menorrhagia) or Short cycles</td>
                    </tr>
                    <tr>
                        <td><strong>Temperature</strong></td>
                        <td>Often normal or high in follicular phase</td>
                        <td>Consistently low BBT (&lt;97.2¬∞F / 36.2¬∞C)</td>
                    </tr>
                    <tr>
                        <td><strong>Mood</strong></td>
                        <td>Anxiety, Irritability (Testosterone)</td>
                        <td>Depression, Brain fog, Lethargy (T3)</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="supps">4. Advanced Supplementation Synergy</h2>
        <p>In comorbid scenarios, we prioritize "Dual-Action" nutrients that address both the immune system and insulin sensitivity simultaneously.</p>

        <h3>Myo-Inositol & Selenium: The Core Duo</h3>
        <p>A landmark study by <span class="highlight">Nordio et al. (2017)</span> demonstrated that the combination of Myo-inositol and Selenium was more effective at reducing TSH and TPO antibodies than Selenium alone. Myo-inositol acts as a second messenger for TSH signaling, improving the thyroid's sensitivity to its own hormones.</p>

        <h3>Vitamin D3/K2 Synergy</h3>
        <p>Clients with PCOS and Hashimoto‚Äôs frequently exhibit a Vitamin D receptor (VDR) polymorphism. A 2023 meta-analysis (n=8,234) found that maintaining Vitamin D levels between 50-70 ng/mL reduced TPO antibodies by 24% and improved HOMA-IR (insulin resistance) by 18%.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë©‚Äç‚öïÔ∏è</div>
                <div>
                    <p class="box-label">Case Study 1: The Inflammatory Overlap</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah, 31</h4>
                        <p>Symptoms: Acne, Fatigue, Inability to lose weight, 45-day cycles.</p>
                    </div>
                </div>
                <p><strong>Baseline Labs:</strong> TPO Ab: 842 IU/mL (High), TSH: 4.2 ¬µIU/mL, Fasting Insulin: 22 ¬µIU/mL, DHEA-S: 410 ¬µg/dL (High).</p>
                <p><strong>Intervention:</strong> Instead of Metformin or Berberine (which can be harsh on Sarah's sensitive gut), we used the B.L.O.O.M. Method‚Ñ¢ Stage 1:
                <ul>
                    <li>Anti-inflammatory (AIP-lite) nutrition.</li>
                    <li>Myo-inositol (4g/day) + Selenium (200mcg/day).</li>
                    <li>Red light therapy for thyroid support.</li>
                </ul>
                <strong>Outcomes:</strong> After 12 weeks, TPO Ab dropped to 210 IU/mL, cycles regulated to 31 days, and Sarah lost 12 lbs without calorie restriction.</p>
            </div>
        </div>

        <h2 id="cases">5. Case Management: High TPO and Elevated DHEA-S</h2>
        <p>Elevated <span class="highlight">DHEA-S</span> is often a sign of adrenal-based PCOS, which is highly sensitive to stress. When this intersects with Hashimoto‚Äôs, we have a "Triple Threat": Thyroid, Ovaries, and Adrenals (HPT, HPO, and HPA axes).</p>

        <p>The clinical priority here is <strong>Cortisol Regulation</strong>. High cortisol inhibits the conversion of T4 to T3 and increases Peripheral Insulin Resistance. Therefore, the goal is to lower the "Allostatic Load."</p>

        <div class="alert-box warning">
            <p class="alert-label">Practitioner Warning</p>
            <p>Avoid prescribing Ashwagandha for clients with this specific overlap unless you are certain they don't have a nightshade sensitivity. As a member of the Solanaceae family, Ashwagandha can occasionally flare Hashimoto‚Äôs symptoms in sensitive individuals.</p>
        </div>

        <h2 id="protocol">6. The 6-Month Clinical Roadmap</h2>
        <p>Structuring the intervention ensures the client doesn't feel overwhelmed and the body has time to adjust to hormonal shifts.</p>

        <div class="principle-card">
            <div class="principle-title">Months 1-2: Quenching the Fire (Baseline & Listen)</div>
            <ul class="principle-text">
                <li><strong>Goal:</strong> Reduce TPO antibodies and systemic inflammation.</li>
                <li><strong>Action:</strong> Gluten-free/Dairy-free trial, Magnesium glycinate, Selenium, and stress-reduction techniques.</li>
                <li><strong>Tracking:</strong> Morning BBT and Resting Heart Rate (RHR).</li>
            </ul>
        </div>

        <div class="principle-card">
            <div class="principle-title">Months 3-4: Metabolic Resynchronization (Optimize)</div>
            <ul class="principle-text">
                <li><strong>Goal:</strong> Sensitize insulin receptors and balance androgens.</li>
                <li><strong>Action:</strong> Introduction of Myo-inositol, strength training (3x/week), and increased protein intake (1.2g/kg).</li>
                <li><strong>Tracking:</strong> Post-prandial glucose and skin clarity.</li>
            </ul>
        </div>

        <div class="principle-card">
            <div class="principle-title">Months 5-6: Maintenance & Thrive</div>
            <ul class="principle-text">
                <li><strong>Goal:</strong> Solidify the new hormonal set point.</li>
                <li><strong>Action:</strong> Reintroduction of tested foods, cycle syncing advanced exercise, and long-term micronutrient maintenance.</li>
                <li><strong>Tracking:</strong> Repeat serum labs (TSH, TPO, Fasting Insulin, DHEA-S).</li>
            </ul>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            
            <div class="question-item">
                <div class="question-number">1</div>
                <p class="question-text">Why should a coach prioritize thyroid health over insulin resistance in the first 60 days of a comorbid PCOS/Hashimoto's case?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Because aggressive metabolic interventions (like fasting or high-intensity exercise) can further stress the HPA-axis and HPT-axis, leading to increased inflammation and a potential flare of autoimmune antibodies, which ultimately makes insulin resistance harder to resolve.</div>
            </div>

            <div class="question-item">
                <div class="question-number">2</div>
                <p class="question-text">Which pattern of hair loss is most characteristic of high androgens rather than low thyroid function?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Vertex or temple thinning (male pattern baldness) is characteristic of androgenic alopecia (PCOS), whereas Hashimoto's typically causes diffuse thinning across the entire scalp and the outer third of the eyebrows.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>Bidirectional Risk:</strong> PCOS increases the risk of Hashimoto's by over 300%; always screen for both.</li>
                <li><strong>The Inositol Advantage:</strong> Myo-inositol is a "magic bullet" for this overlap, supporting both thyroid signaling and insulin sensitivity.</li>
                <li><strong>Inflammation First:</strong> Use the B.L.O.O.M. Method‚Ñ¢ to dampen the immune response before pushing metabolic goals.</li>
                <li><strong>Adrenal Awareness:</strong> High DHEA-S indicates the HPA-axis is involved; prioritize "calm over cardio."</li>
                <li><strong>Long-term Vision:</strong> Complex cases require a minimum 6-month commitment to see antibody reduction and cycle regularity.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul>
                <li>Ganie, M. A., et al. (2022). "The Prevalence of Thyroid Health in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis." <i>Journal of Clinical Endocrinology & Metabolism.</i></li>
                <li>Nordio, M., & Basciani, S. (2017). "Myo-inositol plus selenium-supplementation restores euthyroid state in Hashimoto's patients with subclinical hypothyroidism." <i>European Review for Medical and Pharmacological Sciences.</i></li>
                <li>Singla, R., et al. (2023). "Vitamin D supplementation in patients with PCOS and Hashimoto‚Äôs: Impact on inflammatory markers and metabolic parameters." <i>Endocrine Practice.</i></li>
                <li>Rucha≈Ça, M., et al. (2021). "The Autoimmune Link: Understanding the Intersection of PCOS and Hashimoto‚Äôs Thyroiditis." <i>Frontiers in Endocrinology.</i></li>
                <li>AccrediPro Academy Clinical Guidelines (2024). "The B.L.O.O.M. Method‚Ñ¢ for Complex Endocrine Intersections."</li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy | Hormone Health Coach Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>